摘要
目的:观察埃克替尼(icotinib)治疗晚期肺腺癌非吸烟患者的早期临床疗效。方法:收集17例口服埃克替尼晚期肺腺癌非吸烟患者的临床资料,统计症状缓解时间、KPS评分变化、客观有效率、不良反应。结果:症状缓解时间4～10 d,KPS评分升高率为70.6%(12例),完全缓解率(CR)0%,部分缓解率(PR)为52.9%(9例),疾病稳定率(SD)为35.3%(6例),疾病进展率(PD)为11.8%(2例)。一线治疗9例,CR 0%,PR 66.7%(6例),SD 11.1%(1例),PD 22.2%(2例)。二线及以上治疗8例,CR 0%,PR37.5%(3例),SD 62.5%(5例),PD 0%(0例)。轻度皮肤干燥、皮疹、腹泻不良反应发生率分别为23.5%,11.8%,11.8%,均为轻度。结论:埃克替尼治疗晚期肺腺癌非吸烟患者疗效较好,一线治疗疗效显著,不良反应轻微。
Objective：To investigate the clinical efficacy of icotinib in treatment of non-smokers with advanced lung adenoearcinoma. Methods：Seventeen non-smokers with stage IV lung adenocarcinoma were enrolled into the study. The regimen was oral intake of icotinib until the disease progression. The response rate, quality of life, adverse reactions of icotinib and relief of clinical symptom were observed. Results： Symptom relief started at d 4- 10, 12 cases （70.6%） has improved KPS score, complete respose（CR） rate was 0%, partial response（PR） rate was 52.9% （9 cases） , stable disease（SD） rate was 35.3% （6 cases） , progressive disease（PD） rate was 11.8% （2 cases）. There were 9 cases with first-line therapy, CR 0%, PR 66.7% （6 cases）, SD 11.1% （1 cases）, PD 22.2% （2 cases）. There were 8 cases with second-line therapy, CR 0% , PR 37.5% （3 cases） , SD 62.5% （5 cases）, PD 0%. The major adverse reactions included low-grade dry skin（23.5% ）, rash（ 11.8% ） and diarrhea（ 11.8% ）. Conclusion： Icotinib was effective for non-smokers with advanced lung adenocarcinoma even in first-line therapy. The adverse reaction of icotinib were slight as well.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2012年第14期1651-1653,共3页
Chinese Journal of New Drugs
